Montisera presenting novel solutions at European Parliament

Montisera turns christmas tree into health benefiting solution - showcase at the European Parliament

(Montisera, Raisio; 5 September 2017) – Montisera Ltd, a Finnish development company focused on developing and commercialising bioactive compounds, joins today the top of the line Finnish bioeconomy companies in an exhibition at the European Parliament.

The exhibition showcases more than 50 wood-based solutions for the needs of packaging, hygiene, health care, construction, textile, chemical and pharmaceutical industries. Material solutions from altogether 20 different actors will be presented. The New Wood initiative is organising the event, and the aim of the exhibition is to encourage decision-makers to support the use and further development of wood-based innovations. 

According to MEP Henna Virkkunen (National Coalition Party), who is hosting the exhibition, the aim of the exhibition is also to increase confidence in the diverse and resource efficient use of wood as a raw material particularly amongst European decision-makers. 

Montisera is one of the invited companies to present its’ spruce derived extract for the prevention and treatment of lower urinary tract diseases. With this patented product, Montisera won last year the New Wood initiative competition sub category “Changes in population structure”. Montisera and its’ spruce extract product was also nominated in 2017 as the “Best Finnish bioeconomy company” in Kasvu Open competition. “It is extremely important to show all the possibilities the wood can turn into. The medicaments for human and animals are one of the most valuable products the forest can produce. We are proud to join the Finnish companies at the exhibition”, says Heikki Vuorikoski, founder and Business Development Director of Montisera.

Official New Wood initiative press release of the event and exhibition can be found from here, and the New wood web pages from here.

For further information please contact:
Heikki Vuorikoski, Montisera Ltd. heikki.vuorikoski@montisera.com, tel. +358 40 756 2427
Eveliina Pokela, New Tree initiative eveliina.pokela@uusipuu.fi, tel.+358 44 560 0006
Janiika Vilkuna-Räsänen, European Parliament,  janiika.vilkuna@europarl.europa.eu, tel. +32 49 133 2480

Montisera Ltd
Founded in 2012, Montisera is a privately-owned Finnish development company focused on discovering, developing and commercialising bioactive compounds from its development platform to be used in novel products in the pharmaceutical and food industries. The company is located in Smart Chemistry Park in Raisio, Finland together with several innovative chemical industry companies. Montisera’s focus is on the management of its global partner network of universities, science companies, laboratories, contract research organisations (CROs) etc. Montisera currently has three bioactive compounds in its development platform in different stages of the development pipeline, ranging from Parkinson’s disease to alcoholism and lower urinary tract diseases.

Montisera initiates of the company's spruce hemicellulose pilot production

Montisera receives major governmental funding from Tekes for initiating the pilot production of the company’s spruce hot water extract molecule

(Montisera Ltd, Raisio; 14 September 2016 at 12:14) – Montisera, a Finnish development company focused on developing and commercialising bioactive compounds, have announced today that Tekes, the Finnish Funding Agency for Innovation has granted Montisera major governmental funding to support product development for the initiation of the company’s spruce hemicellulose pilot production. Montisera spruce extract has been found to have a positive effect in the treatment of lower urinary tract diseases. Early in February the spruce extract molecule was awarded first prize in the ¨Demographic changes” category  in the ¨New Tree 2017¨ competition, and the second prize in the overall competition.

”Tekes support enables us to initiate a vital, optimal scale pilot production phase”, says Mira Povelainen, CEO of the company. ”The funding is significant for the company as well as for our network of cooperating companies. Product development will progress according to schedule with the help of the funding .”

”It is remarkable that the results of Finnish top level academic research will be carried over to an industrial pilot production phase with Finnish resources,” says Heikki Vuorikoski, founder and business development director of the company. ”On a global scale, as many as 60% of men aged 50-60, and more than 90% of men above the age of 80 suffer from lower urinary tract diseases. Today there is no effective treatment for these problems.”

For further information please contact:
Mira Povelainen, CEO, Montisera Ltd. tel. +358 578 9692

Montisera Ltd
Founded in 2012, Montisera is a privately owned Finnish development company focused on discovering, developing and commercialising bioactive compounds from its development platform to be used in novel products in the pharmaceutical and food industries. Montisera’s focus is on the management of its global partner network of universities, science companies, laboratories, contract research organisations (CROs) etc. Montisera currently has three bioactive compounds in its development platform in different stages of the development pipeline, ranging from Parkinson’s disease to alcoholism and lower urinary tract diseases.